Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4
By the Serve You Rx Clinical Department References The Lancet
Tirzepatide (Zepbound, Mounjaro) is a dual GIP/GLP-1 receptor agonist that typically promotes significant weight loss by reducing appetite and slowing gastric emptying
They do not forecast how you will respond to any specific drug, but they do describe the biology a clinician is prescribing into
CTS gets worse over time, and its harder to manage in its later stages
Participants receiving tirzepatide at the maximum dose lost an average of 22.5% of baseline body weight over 72 weeks, compared to 14.9% for semaglutide and 6.2% for placebo
Ozempic affects blood sugar and can have side effects such as nausea, vomiting, or pancreatitis in rare cases
US$ 20.50
US$ 29.17
US$ 26.81
